Impact of Enoxaparin on Hemoglobin and Platelet Parameters in Post‐Cesarean Venous Thromboembolism Prophylaxis: A Retrospective Cohort Study

Aim To evaluate the effects of a 10‐day postpartum enoxaparin regimen on hemoglobin (HB) levels and platelet indices in women receiving post‐cesarean venous thromboembolism (VTE) prophylaxis. Methods This retrospective cohort study was conducted at a tertiary care center between December 2022 and June 2025. A total of 141 women who underwent cesarean section and had available hemogram data on postoperative day 10 were included. Patients were categorized into those who received enoxaparin prophylaxis ( n = 112) and those who did not ( n = 29). HB, hematocrit (HCT), platelet count (PLT), plateletcrit (PCT), mean platelet volume (MPV), platelet distribution width (PDW), and platelet large cell ratio (PLCR) were evaluated preoperatively, at 6 h postoperatively, and on the 10th postoperative day. The difference between postoperative 10th day and postoperative 6th hour laboratory values was also analyzed among groups receiving no enoxaparin, 40, or 60 mg/day of enoxaparin. Results No statistically significant differences were observed between the enoxaparin and non‐enoxaparin groups in HB or platelet parameters on the 10th postoperative day ( p > 0.05). The differences in hematologic indices between the 10th postoperative day and the 6th postoperative hour did not show significant variation among the dosing groups. Conclusion In our study, we did not observe a significant effect of a 10‐day enoxaparin regimen used for postoperative VTE prophylaxis in cesarean patients on HB levels or platelet indices. However, given our limited sample size, its hematologic safety should be confirmed through larger prospective studies.